Associated tags: Oncology, Patient, Hospital, PharMerica, FDA, Pharmaceutical, Health, Specialty pharmacy, Pharmaceutical industry, Clinical Trials, United, Diagnosis, Death, Pharmacy, National Cancer Institute, SEER, Epidemiology
Locations: LOUISVILLE, KY, US, UNITED STATES, NORTH AMERICA, KENTUCKY
Insurance,
Day One,
Patient,
Health care,
Brain,
FDA,
Pharmacy,
Health,
Cancer,
LGG,
BRAF,
BRAF V600,
Central nervous system,
Pharmaceutical industry LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
Key Points:
- LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that its company, Onco360®, one of the nation’s largest independent oncology pharmacies, is being selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for children diagnosed with certain central nervous system tumors.
- LGG is the most common central nervous system tumor in children, representing 30% of pediatric brain tumors.
- BRAF is the most commonly altered gene in pediatric LGG, as 75% of patients have BRAF alterations.
- We’re proud to partner with Day One Biopharmaceuticals to become a specialty provider for OJEMDA™,” said Benito Fernandez, Chief Commercial Officer at Onco360®.
Retrieved on:
Wednesday, April 10, 2024
FDA,
Cancer,
Pharmacy,
Hub,
Blood,
Eculizumab,
Ravulizumab,
Insurance,
Alexion Pharmaceuticals,
Disease,
EVH,
Patient,
Haematopoietic system,
Hemolysis,
Alexion,
Health care,
Immune system,
PNH,
Quality of life,
Anemia,
Pharmaceutical industry LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).
Key Points:
- LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).
- Voydeya® is FDA-approved as add-on therapy to Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients living with PNH that experience continued anemia, or EVH.
- This innovative drug will complement current treatment regimens and help regulate the immune system, providing control and preventing the destruction of healthy blood cells.
- To learn more about Onco360® and BrightSpring, please visit https://www.brightspringhealth.com/ .
Immune system,
PNH,
Specialty pharmacy,
Patient,
Ravulizumab,
FDA,
Eculizumab,
Paroxysmal nocturnal hemoglobinuria,
EVH,
Blood,
Alexion Pharmaceuticals LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor.
Key Points:
- LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor.
- It is FDA-approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in combination with C5 inhibitor, Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients that experience clinically significant extravascular hemolysis (EVH).1 Voydeya® is an oral, Factor D inhibitor that acts in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels.
- “Onco360 appreciates the opportunity to partner further with the team at Alexion and become the sole national specialty pharmacy provider for Voydeya®”, said Benito Fernandez, Chief Commercial Officer.
- “We are proud to add this first in class oral Factor D inhibitor treatment option for PNH patients.”
Diagnosis,
Health care,
Disease,
Selinexor,
Partnership,
Patient,
Pharmacy,
Multiple myeloma,
Pharmacist,
Cancer,
B cell,
NPS,
Insurance,
Patient satisfaction,
DLBCL,
Health,
Hospital “At BrightSpring Health Services, we are proud of our leading service lines like Onco360® as we continue to innovate in the health care industry and provide patients with life-improving and life-sustaining treatments,” said BrightSpring President and CEO Jon Rousseau.
Key Points:
- “At BrightSpring Health Services, we are proud of our leading service lines like Onco360® as we continue to innovate in the health care industry and provide patients with life-improving and life-sustaining treatments,” said BrightSpring President and CEO Jon Rousseau.
- “It is an honor for Onco360® to be selected as the preferred pharmacy for XPOVIO® (selinexor) and shows the Company’s dedication to innovation, quality patient care and improving health outcomes.
- Onco360® and its dedicated employees do a fantastic job of keeping BrightSpring’s important mission at the core of everything they do.”
As another demonstration of BrightSpring and Onco360®’s commitment to patient care, this year, Onco360® celebrates excellent service and care that resulted in unmatched patient satisfaction scores.
- “It’s incredibly important to us to provide patient care that prioritizes expertise, reliability, consistency, and overall satisfaction,” said Benito Fernandez, Chief Commercial Officer at Onco360®.
LOUISVILLE, Ky., March 14, 2024 (GLOBE NEWSWIRE) -- This year, Onco360®, the nation’s leading independent specialty oncology pharmacy, celebrates excellent service and care that resulted in unmatched patient satisfaction scores.
Key Points:
- LOUISVILLE, Ky., March 14, 2024 (GLOBE NEWSWIRE) -- This year, Onco360®, the nation’s leading independent specialty oncology pharmacy, celebrates excellent service and care that resulted in unmatched patient satisfaction scores.
- Onco360®’s net promoter score (NPS) saw an 11-point increase, reaching an impressive 94, while the rest of the industry averaged 74 points.
- “At Onco360®, we are committed to improving the lives of patients battling cancer and our recent net promoter score proves that our personalized services and specialized teams are making a positive difference in the lives of those we serve,” said Benito Fernandez, Chief Commercial Officer.
- In fact, 94% of Onco360® patients reported they would be upset if forced to use a different specialty pharmacy.
Retrieved on:
Wednesday, March 13, 2024
Oncology,
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Diagnosis,
B-cell lymphoma,
Dexamethasone,
Selinexor,
Partnership,
Bortezomib,
Patient,
Carfilzomib,
National Cancer Institute,
Multiple myeloma,
B cell,
Lenalidomide,
Daratumumab,
Therapy,
Bone marrow,
Food,
FDA,
DLBCL,
Follicular lymphoma,
Pharmaceutical industry Onco360®, the nation’s largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm’s product XPOVIO® (selinexor), a first-in-class, XPO-1 inhibitor.
Key Points:
- Onco360®, the nation’s largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm’s product XPOVIO® (selinexor), a first-in-class, XPO-1 inhibitor.
- “Onco360 is excited to expand our partnership with the team at Karyopharm and become the preferred national specialty pharmacy partner for XPOVIO,” said Benito Fernandez, Chief Commercial Officer.
- Multiple myeloma is an incurable hematological malignancy involving plasma cells.
- Only 50 percent of patients diagnosed with multiple myeloma survive past five years following initial diagnosis.
Retrieved on:
Wednesday, December 20, 2023
Science,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
FDA,
Clinical Trials,
Patient,
Specialty pharmacy,
Bone marrow failure,
Immune system,
Pharmacy,
Thrombosis,
Blood,
Hemolysis,
PNH,
RBC,
Novartis,
Mutation,
Medication,
Paroxysmal nocturnal hemoglobinuria “Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.
Key Points:
- “Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.
- Every year, roughly 500 patients in the U.S. are diagnosed with PNH.3 An estimated 10-16 cases per million patients around the world have PNH.
- Most patients are diagnosed with PNH in their 30s and 40s.
- Please see the full Prescribing Information for Fabhalta, including Boxed WARNING and Medication Guide.®
Retrieved on:
Thursday, November 30, 2023
Oncology,
Health,
FDA,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Cough,
Woman,
Aggressive fibromatosis,
Therapy,
Toxicity,
Rash,
Progression-free survival,
Stomatitis,
Abdominal pain,
Upper respiratory tract infection,
Headache,
Specialty pharmacy,
Risk,
Fatigue,
Patient,
Pharmacy,
PFS,
Plantar fibromatosis,
Diarrhea,
Nausea,
HIV disease progression rates,
Pharmaceutical industry,
Medical imaging Ogsiveo™ is an oral gamma secretase inhibitor for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.
Key Points:
- Ogsiveo™ is an oral gamma secretase inhibitor for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.
- “Onco360 is excited to partner with the team at SpringWorks Therapeutics and become a specialty pharmacy partner for Ogsiveo™,” said Benito Fernandez, Chief Commercial Officer.
- Desmoid tumors mostly affect people between the ages of 15 and 60 years, but they can occur at any age.
- In children, desmoid tumors most often occur between the ages of 15 and 16 years.
Retrieved on:
Wednesday, November 29, 2023
Oncology,
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Vomiting,
AstraZeneca,
Neutrophil,
Toxicity,
Stomatitis,
Incidence,
National Cancer Institute,
Fulvestrant,
White,
Specialty pharmacy,
Lymphocyte,
PIK3CA,
Breast cancer,
Fatigue,
Patient,
Pharmacy,
PFS,
PTEN,
FDA,
Neoplasm,
Creatinine,
HER2,
Diarrhea,
Nausea,
Cancer,
Diagnosis,
Death,
AKT1,
Recurrence,
HIV disease progression rates,
Triglyceride,
Pharmaceutical industry Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap™ (capivasertib).
Key Points:
- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap™ (capivasertib).
- FDA also approved the FoundationOne®CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with capivasertib with fulvestrant.
- “Onco360 is excited to partner with the team at AstraZeneca and become a specialty pharmacy provider for Truqap™,” said Benito Fernandez, Chief Commercial Officer.
- “We continue to see therapeutic advancements that support our mission; to improve the lives of patients battling cancer, rare, and orphan disease.
Retrieved on:
Tuesday, November 21, 2023
Oncology,
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Lancet,
National Cancer Institute,
Jazz Pharmaceuticals,
Takeda,
CRC,
Specialty pharmacy,
Anti-VEGF,
VEGFR-3,
Mortality,
Patient,
Pharmacy,
Large intestine,
VEGF,
Caregiver,
PharMerica,
Colorectal cancer,
Cancer,
Diagnosis,
Metastasis,
Death,
Hospital,
Irinotecan,
JAMA,
Pharmaceutical industry Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.
Key Points:
- Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.
- Colorectal cancer is the fourth most frequent diagnosed cancer and second leading cause of death in the U.S.
- Fruquintinib vs Placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicenter, randomized double blind, phase 3 study.
- Effect of fruquintinib vs Placebo on overall survival in patients with previously treated metastatic colorectal cancer.
